Skip to content

Based on the association study of intestinal microecology and TCM tongue diagnosis study on the establishment of a precise diagnosis and treatment system for membranous nephropathy in traditional Chinese medicine

Based on the association study of intestinal microecology and TCM tongue diagnosis study on the establishment of a precise diagnosis and treatment system for membranous nephropathy in traditional Chinese medicine

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004625
Enrollment
Unknown
Registered
2021-03-24
Start date
2021-03-30
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD MN

Interventions

Sponsors

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Idiopathic membranous nephropathy group: (1) It meets the diagnostic criteria of Western medicine and is confirmed to be an IMN patient by renal biopsy and clinical examination; (2) 24-hour urine protein quantitative >= 1g, eGFR > 30ml/min/1.73m2; (3) 18-75 years old, regardless of gender or ethnicity; (4) The patient gave informed consent and signed the informed consent form. 2. CKD group of non-membranous nephropathy: (1) Non-MN patients who meet the diagnostic criteria of Western medicine and are confirmed by renal biopsy; (2) 24-hour urine protein quantitative >= 1g, eGFR > 30ml/min/1.73m2; (3) 18-75 years old, regardless of gender or ethnicity; (4) The patient gave informed consent and signed the informed consent form. 3. Healthy volunteer group: (1) Healthy adults, between the ages of 18-75, regardless of gender or ethnicity; (2) The patient gave informed consent and signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Rapidly progressing CKD; (2) Merge other pathological types of MN; (3) Have received immunosuppressant or cytotoxic drug treatment for more than 4 weeks in the past 6 months; (4) Have received glucocorticoids (prednisone or prednisone) at a dose of more than 20 mg/d for more than 4 weeks in the past 6 months; (5) Those with life-threatening complications such as severe infections; (6) Those with positive HBV serological indicators other than HbsAb and those with abnormal transaminase in continuous liver function tests; (7) Patients with malignant tumors or patients with malignant tumor history, history of HIV infection, history of mental illness, acute central nervous system disease, severe gastrointestinal disease, and patients who are prohibited from using immunosuppressive agents; (8) Poor blood sugar control, fasting blood sugar >= 7.0mmol/L; (9) Pregnant or lactating women; (10) Undergoing other clinical trials and research; (11) Combined with serious diseases and dysfunction of other organs; (12) Taking probiotics for treatment in the past month; (13) Take antibiotic treatment in the past 3 months; (14) Hypertension has poor blood pressure control, blood pressure >= 140/90mmHg; (15) Those who are deemed unsuitable to participate in this research after the comprehensive evaluation of the research.

Design outcomes

Primary

MeasureTime frame
Intestinal flora;Scr;

Countries

China

Contacts

Public ContactWang Lin

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

happytlynn@163.com+86 13585614134

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026